Special Issue "Thrombocytopenia and ITP: Causes, Symptoms, and Treatment"

A special issue of Journal of Clinical Medicine (ISSN 2077-0383).

Deadline for manuscript submissions: closed (31 October 2016).

Special Issue Editors

Prof. Dr. Amy E. Geddis
E-Mail Website
Guest Editor
Pediatric hematology oncology, University of California, San Diego and Rady Children’s Hospital San Diego, 3020 Children’s Way, San Diego, CA 92123, USA
Interests: megakaryopoiesis; thrombopoietin signaling; immune thrombocyoptenia; inherited thrombocytopenia
Dr. Michele P. Lambert
E-Mail Website
Guest Editor
Perlman School of Medicine at the University of Pennsylvania and the Children’s Hospital of Philadelphia, 34th St and Civic Center Blvd, Philadelphia, PA 19104, USA
Interests: megakaryopoiesis; immune thrombocyoptenia; inherited thrombocytopenia; genetics of inherited thrombocytopenias

Special Issue Information

Dear Colleagues,

Thrombocytopenia encompasses a diverse range of conditions, ranging from acquired to constitutive.  With the availability of high throughput molecular techniques, new insights into the etiology of immune and inherited thrombocytopenia syndromes have markedly  improved our ability to diagnose and counsel patients accurately and promise to aid in the development of novel therapeutics.

This Special Issue of the Journal of Clinical Medicine will cover the following important aspects of this field:

  • Molecular understanding of thrombopoiesis
  • Molecular basis of inherited platelet defects
  • Leukemia predisposition in inherited thrombocytopenia syndromes
  • Mechanisms of immune dysregulation in immune thrombocytopenia
  • New therapeutic developments

Prof. Dr. Amy E. Geddis
Dr. Michele P. Lambert
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • thrombocytopenia
  • megakaryopoiesis
  • inherited thrombocytopenia
  • thrombopoietin
  • immune thrombocytopenia
  • leukemia predisposition
  • whole exome sequencing

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Review

Open AccessReview
Pathogenesis and Therapeutic Mechanisms in Immune Thrombocytopenia (ITP)
J. Clin. Med. 2017, 6(2), 16; https://doi.org/10.3390/jcm6020016 - 09 Feb 2017
Cited by 133 | Viewed by 11190
Abstract
Immune thrombocytopenia (ITP) is a complex autoimmune disease characterized by low platelet counts. The pathogenesis of ITP remains unclear although both antibody‐mediated and/or T cell‐mediated platelet destruction are key processes. In addition, impairment of T cells, cytokine imbalances, and the contribution of the [...] Read more.
Immune thrombocytopenia (ITP) is a complex autoimmune disease characterized by low platelet counts. The pathogenesis of ITP remains unclear although both antibody‐mediated and/or T cell‐mediated platelet destruction are key processes. In addition, impairment of T cells, cytokine imbalances, and the contribution of the bone marrow niche have now been recognized to be important. Treatment strategies are aimed at the restoration of platelet counts compatible with adequate hemostasis rather than achieving physiological platelet counts. The first line treatments focus on the inhibition of autoantibody production and platelet degradation, whereas second‐line treatments include immunosuppressive drugs, such as Rituximab, and splenectomy. Finally, thirdline treatments aim to stimulate platelet production by megakaryocytes. This review discusses the pathophysiology of ITP and how the different treatment modalities affect the pathogenic mechanisms. Full article
(This article belongs to the Special Issue Thrombocytopenia and ITP: Causes, Symptoms, and Treatment)
Show Figures

Graphical abstract

Back to TopTop